Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
Study: Risk of Atrial Fibrillation Remains High After 3 Years, Including Those With Heart Failure
November 6th 2023Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.
Read More
Lenacapavir Demonstrates Small Margin of Resistance for Those Heavily Treated With HIV
October 25th 2023Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.
Read More
Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
October 19th 2023The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Read More
AMCP Session Provides Updates on PBM Reform Efforts Currently Stalled in Congress
October 17th 2023Reform efforts to consider how health care plans may capitalize on disclosures, balancing out-of-pocket spending access, and how pharmacists can help plan members with the increased transparency of pharmacy benefit managers.
Read More
Updates in Federal Legislation Addressing Digital Therapeutics, Access to Care
October 17th 2023Although all legislation is currently on hold in Congress, there are important actions under consideration for pharmacy, including digital therapeutics, access to care, and health care disparities.
Read More
Study: No Difference Found in Safety of Reference Biologic, Biosimilar
October 9th 2023In the first systematic review using statistical methods, investigators found switching from a reference biologic to a biosimilar was comparable in safety, but no conclusion on immunogenicity could be drawn.
Read More